Low-dose guar improves diabetic control

Jones, D. B.; Lousley, S.; Jelfs, R.; Slaughter, P.; Carter, R. D.; Mann, J. I.
July 1985
Journal of the Royal Society of Medicine;Jul1985, Vol. 78 Issue 7, p546
Academic Journal
Twenty diabetic outpatients (12 non-insulin-treated and 8 insulin-treated) were given guar granulate in a dose of 10 g daily for two months in order to study the effect on glycaemic control and lipid levels. Mean glycosylated haemoglobin levels (HbA1c%) fell from 1.1± 2.0% pre-guar to 10.5 ± 2.2% (P< 0.001) after one month on guar and to 10.1±2.3% (P<0.0001) after two months. Following discontinuation of guar, HbA1c% rose to 11.1±2.5% (P<0.002). However, there were no significant changes in fasting blood glucose, 1 h postprandial blood glucose following a test meal, 24 h urinary glucose excretion or in lipid levels. Gastrointestinal side effects occurred in 4 patients during treatment with guar. Four patients reduced their dose of insulin and 2 patients reduced their dose of sulphonylurea therapy during this time because of symptoms suggestive of hypoglycaemia. We suggest that the low dose of guar used in this study may help improve glycaemic control in diabetic patients and that this may be achieved with a low incidence of gastrointestinal side effects.


Related Articles

  • Clinical Experience With the Addition of Pramlintide in Patients With Insulin-Requiring Type 2 Diabetes. Elkind-Hirsch, Karen; Butler, William J.; Bhushan, Madhu; Hirsch, David; Bhushan, Rajat // Diabetes Care;Jan2008, Vol. 31 Issue 1, p39 

    The article focuses on a study that involved adding pramlintide in patients with insulin-requiring type 2 diabetes. According to it, pramlintide added to insulin treatment in patients with type 2 diabetes was shown to reduce postprandial glucose levels, improve glycemic control, and promote...

  • Target for Glycemic Control. Monnier, Louis; Colette, Claude // Diabetes Care;Nov2009 Supplement, Vol. 32, pS199 

    The article explores the role of glycated hemoglobin (A1C) in the management of type 2 diabetes. It says that glucose testing is more effective during postprandial at four hours after a meal and postabsorptive period six hours after the postprandial period. Based on the own study of the authors,...

  • Insulin glargine as effective as lispro in controlling HbA1c. Bloomgarden, Zachary T. // Endocrine Today;6/10/2008, Vol. 6 Issue 10, p16 

    The article reports on a study about the efficacy of insulin glargine and lispro in controlling glycosylated hemoglobin (HbA1c) levels among type 2 diabetes patients. Under the study, type 2 diabetics on oral hypoglycemic agents were administered with either once-daily insulin glargine or...

  • Dipeptidyl peptidase-4 inhibitor in a patient with end-stage renal disease and type 2 diabetes. Mee Onn Chai; Noble-Bell, Georgia // Journal of Renal Nursing;Jul2015, Vol. 7 Issue 4, p180 

    No abstract available.

  • Cdk5-dependent regulation of glucose-stimulated insulin secretion. Fan-Yan Wei; Nagashima, Kazuaki; Ohshima, Toshio; Saheki, Yasunori; Yun-Fei Lu; Matsushita, Masayuki; Yamada, Yuichiro; Mikoshiba, Katsuhiko; Seino, Yutaka; Matsui, Hideki; Tomizawa, Kazuhito // Nature Medicine;Oct2005, Vol. 11 Issue 10, p1104 

    Tight glycemic control in individuals with diabetes mellitus is essential to prevent or delay its complications. Present treatments to reduce hyperglycemia mainly target the ATP-sensitive K+ (KATP) channel of pancreatic beta cells to increase insulin secretion. These current approaches are often...

  • Effect of antihyperglycaemic agents added to metformin and a sulfonylurea in type 2 diabetes.  // Australian Journal of Pharmacy;Nov2011, Vol. 92 Issue 1098, p90 

    The article examines the effect of adding a third antihyperglycaemic drug (AHD) to the ongoing metformin and sulfonylurea medication, when blood glucose control is not achieved in patients with type 2 diabetes. Results of studies conducted to evaluate the effect of AHD on glycemic control and...

  • Intensive glucose lowering (HbA1c target<6.0%) for people with type 2 diabetes increases mortality. Shaw, Jonathan E. // Evidence Based Medicine;Dec2011, Vol. 16 Issue 6, p186 

    The article presents a study that deals with long-term effects of intensive glucose lowering on cardiovascular outcomes. The study focuses on the Action to Control Cardiovascular Risk in Diabetes trial which aimed to address the uncertainty on the role of lowering blood glucose in reducing the...

  • Empagliflozin: A sodium--glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. DIXIT, DIVISHA; YOUNGMIN YOON; VOLINO, LUCIO R.; PATEL MANSUKHANI, RUPAL // American Journal of Health-System Pharmacy;11/15/2015, Vol. 72 Issue 22, p1943 

    Purpose. The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse effects, dosage and administration, and drug--drug interactions of empaglilozin are reviewed. Summary. Empagliflozin is a direct inhibitor of sodium--glucose cotransporter 2 (SGLT2), which acts to lower the...

  • Review: Intensive insulin pump therapy slightly improves glycemic control in type 1 diabetes. Kudva, Yogish C. // ACP Journal Club;Sep/Oct2002, Vol. 137 Issue 2, p56 

    Compares the efficacy between continuous subcutaneous insulin infusion and multiple insulin injections for glycemic control in patients with type 1 diabetes mellitus. Meta-analysis of randomized controlled trials; Weighted mean differences in blood glucose level, glycated hemoglobin and total...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics